Pralatrexate

Cas No.:	146464-95-1
Synonyms:	Folotyn
SMILES:	C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
Formula:	C23H23N7O5
M.Wt:	477.4726
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines.Pralatrexate is an antifolate (a folate analogue metabolic inhibitor) designed to accumulate preferentially in cancer cells. Based on preclinical studies, researchers believe that Pralatrexate selectively enters cells expressing reduced folate carrier type 1 (RFC-1), a protein that is overexpressed on certain cancer cells compared to normal cells.
Target:	IC50 Value: < 300 nM Target: Antifolate
References:	[1]. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA.,Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study,Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. Epub 2012 Apr 26. [2]. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD.,Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.,J Thorac Oncol. 2012 Jun;7(6):1041-8. [3]. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M.,Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.,Blood. 2012 May 3;119(18):4115-22. Epub 2012 Mar 6. [4]. Casanova M, Medina-Pérez A, Moreno-Beltran M, Mata-Vazquez M, Rueda A.,Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.,Ther Clin Risk Manag. 2011;7:401-8. Epub 2011 Oct 7. [5]. Hui J, Przespo E, Elefante A.,Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.,J Oncol Pharm Pract. 2012 Jun;18(2):275-83. Epub 2011 Sep 26.